Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## DINGDANG HEALTH TECHNOLOGY GROUP LTD.

叮噹健康科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 09886)

## POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON MAY 28, 2024

References are made to the circular (the "Circular") and the notice of annual general meeting (the "Notice of AGM") of Dingdang Health Technology Group Ltd. (the "Company") both dated April 25, 2024. Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

## POLL RESULTS OF THE ANNUAL GENERAL MEETING

The board (the "Board") of directors (the "Directors") of the Company is pleased to announce that the annual general meeting of the Company was held at 3:00 p.m. on Tuesday, May 28, 2024 at Building 1, Yard 50, Dengshikou Street, Dongcheng District, Beijing, the PRC (the "AGM") and all the proposed resolutions (the "Resolutions") set out in the Notice of AGM were duly passed by the shareholders of the Company (the "Shareholders") by way of poll.

As at the date of the AGM, the total number of issued Shares was 1,341,472,897. Excel Returns Group Limited, the platform to directly hold 11,760,000 Shares, representing approximately 0.88% of the total number of issued Shares of the Company, subject to the Pre-IPO Share Option Scheme and the RSU Scheme, did not exercise voting rights attached to any Shares held by it in relation to options or restricted share units which have not been exercised or vested. CMB Wing Lung (Trustee) Limited, as trustee, abstained from exercising voting rights in respect of 20,100,000 Shares held by it (representing approximately 1.5% of the total number of issued Shares of the Company) under trust for the RSU Scheme adopted on June 27, 2023. Accordingly, the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions proposed at the AGM was 1,309,612,897 Shares, representing approximately 97.62% of the total number of issued Shares. Save as disclosed herein, there was (i) no restriction on any Shareholder casting votes on any of the Resolutions at the AGM; (ii) no Shareholder was required to abstain from voting on any of the Resolutions at the AGM under the Listing Rules; (iii) no Share entitling the holder to attend the AGM and abstain from voting in favour of any of the Resolutions at the AGM under Rule 13.40 of the Listing Rules; and (iv) no Shareholder has stated the intention in the Circular to vote against or to abstain from voting on any of the Resolutions at the AGM. The Shareholders, holding in aggregate 816,007,877 Shares, representing approximately 60.83% of the issued Shares, were present in person or by proxy at the AGM.

The poll results in respect of all the Resolutions at the AGM are as follows:

	Ordinary Resolutions		Number of votes (Approximate %)	
Ordinary Resolutions		For	Against	
1.		To receive and adopt the audited consolidated financial statements of the Company, its subsidiaries and its consolidated affiliated entities and the reports of the directors of the Company and auditor (the "Auditor") of the Company for the year ended December 31, 2023.	(100.00%)	0 (0.00%)
2.	(a) i.	To re-elect Mr. Yu Lei as an executive Director.	815,061,877 (100.00%)	0 (0.00%)
2.	(a) ii.	To re-elect Mr. Yu Qinglong as an executive Director.	816,007,877 (100.00%)	0 (0.00%)
2.	(a) iii.	To re-elect Mr. Yang Yibin as an executive Director.	815,061,877 (100.00%)	0 (0.00%)
2.	(a) iv.	To re-elect Ms. Cai Li as a non-executive Director.	815,061,877 (100.00%)	0 (0.00%)
2.	(b)	To authorize the Board to fix the remuneration of the Directors.	815,061,877 (100.00%)	0 (0.00%)
3.		To re-appoint Deloitte Touche Tohmatsu as the Auditor and to authorise the Board to fix its remuneration.	815,061,877 (100.00%)	0 (0.00%)
4.		To grant a general mandate to the Directors to allot, issue and deal with new shares of the Company not exceeding 20% of the Company's total number of issued shares as at the date of passing of this resolution.	(99.89%)	855,880 (0.11%)
5.		To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the Company's total number of issued shares as at the date of passing of this resolution.		0 (0.00%)
6.		To extend the general mandate granted to the Directors to allot, issue and deal with new shares of the Company by the aggregate number of shares repurchased by the Company.	(99.89%)	855,880 (0.11%)
		Special Resolution		
7.		To approve and adopt the fourth amended and restated memorandum and articles of association of the Company and authorise any one of the directors of the Company to do all things necessary to implement the adoption of the fourth amended and restated memorandum and articles of association of the Company.	(100.00%)	0 (0.00%)

For the details of the Resolutions, please refer to the Circular.

As more than 50% of the votes were cast in favour of each of the above Resolutions numbered 1 to 6, all of them were duly passed as ordinary resolutions. As more than 75% of the votes were cast in favour of the above Resolution numbered 7, it was duly passed as a special resolution.

Computershare Hong Kong Investor Services Limited, the branch share registrar and transfer office of the Company in Hong Kong, was appointed as scrutineer at the AGM for the purpose of votetaking.

All Directors of the Company attended the AGM in person or by electronic means.

## By order of the Board DINGDANG HEALTH TECHNOLOGY GROUP LTD. YANG WENLONG

Chairman

Hong Kong, May 28, 2024

As of the date of this announcement, the executive Directors are Mr. YANG Wenlong, Mr. XU Ning, Mr. YU Lei, Mr. YU Qinglong and Mr. YANG Yibin, the non-executive Director is Ms. CAI Li, and the independent non-executive Directors are Mr. ZHANG Shouchuan, Dr. FAN Zhenhong and Mr. JIANG Shan.